GlassScriptPhysician profile
Syed S Ali
NPI 1780844233
$2,587.38
in general payments reported to CMS, 2019-2025
39 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $760 · 2021: $96.63 · 2022: $42.02 · 2023: $72.22 · 2024: $95.23 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477 · Education: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.28 |
| Education | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $401.87 | 2019-2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $208.21 | 2019-2024 | Calquence |
| Fennec Pharmaceuticals, INC. | $197.58 | 2025 | Fyarro |
| Amgen INC. | $179.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $141.67 | 2019-2020 | |
| Olympus America INC. | $112.77 | 2019 | |
| Lilly USA, LLC | $106.34 | 2019-2021 | |
| Emd Serono, INC. | $103.90 | 2019-2020 | |
| Pfizer INC. | $83.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.08 | 2019-2024 | |
| Genentech USA, INC. | $64.55 | 2019-2022 | |
| Astellas Pharma US INC | $63.90 | 2019 | |
| Celgene Corporation | $55.03 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $52.15 | 2020 | |
| Rigel Pharmaceuticals, INC. | $50.87 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.